在雄性注射部位给予3 mg/kg皮肤皮下组织中见到良性纤维瘤增加。在任何剂量未观察到治疗-相关注射部位纤维肉瘤。当前不知道这些发现人相关性。用艾塞那肽,在BYDUREON中活性成分,在雄性和雌性大鼠在剂量18,70,或250 μg/kg/day(根据AUC分别为人全身暴露的3,6,和 27倍)给药通过每天1次皮下丸注射[bolus injection...
药品通用名 注射用艾塞那肽微球(预填充笔) 英文名称 Exenatide Powder And Solvent For Prolonged-Release Suspension For Injection In Pre-Filled Pen 商品名 Bydureon 规格 2mg 剂型 注射剂 持证商 Astrazeneca AB 备注1 未进口原研药品 备注2 欧盟上市 来源分类 暂无权限 来源批次 暂无权限 ...
英文名:Exenatide powder and solvent prolonged-release suspension for injection in pre-filled pen 规格:2mg 持证商:AstraZeneca AB 上市国:欧盟集中上市 在线询价 您正在向SciMed America LLC发送关于产品注射用艾塞那肽微球(预填充笔)Exenatide powder and solvent prolonged-release suspension for injection in ...
Ask your doctor or pharmacist if you don't understand how to use an injection. Do not allow a young child to use this medicine without help from an adult. Bydureon BCise is usually injected once every 7 days. You may give the injection with or without food at any time of the day. Fo...
profuse sweating, or tremors. this document does not contain all possible side effects and others may occur. check with your physician for additional information about side effects. dosage for bydureon bcise the dose of bydureon bcise is 2 mg administered by subcutaneous injection once every seven ...
2 mg injectable suspension, single-dose autoinjector How should I store Bydureon BCise? Bydureon BCise injection liquid should be stored lying flat in its original packaging, in the refrigerator, between 36 F to 46 F (2 C to 8 C). Unused Bydureon BCise can be stored until the expiration ...
The microsphere technology permits a prolonged absorption of exenatide from the subcutaneous depot, which allows one injection per week instead of two injections per day with the initial formulation of exenatide (Byetta). The clinical development programme DURATION showed that exenatide 2 mg once weekly...
Bydureon®(generic nameExenatideMicrospheres for injection) is the first once-weekly hypoglycemic drug launched in China, which is used to improve glycemic control of type 2 diabetes and applicable to the patients not achieving satisfied level of glycemic control in case of taking metformin or sulfo...
About BYETTA® (exenatide) injection BYETTA was the first glucagon-like peptide-1 (GLP-1) receptor agonist to be approved by the FDA for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone GLP-1. GLP-1 improves blood sugar after food...